

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Resources Medical Holdings Company Limited**

### **華潤醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1515)**

- (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;  
(2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR;  
(3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;  
AND  
(4) CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following changes of the composition of the Board and its certain committees that with effect from September 14, 2023: (1) Mr. HU Hui has resigned as a non-executive Director and a member of the Audit Committee; (2) Ms. GE Lu has been appointed as a non-executive Director and a member of the Remuneration Committee; (3) Mr. ZHOU Peng has been appointed as an independent non-executive Director and a member of the Audit Committee; and (4) Mr. KWONG Kwok Kong has resigned as a member of the Remuneration Committee.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. HU Hui (“**Mr. HU**”) has resigned, with effect from September 14, 2023, as a non-executive Director and a member of the audit committee of the Company (“**Audit Committee**”) due to changes in internal work arrangement of China Resources Healthcare Group Limited (華潤健康集團有限公司) (“**CR Health**”), the controlling shareholder of the Company. Mr. HU has confirmed that he has no disagreement with the Board and that there is no matter in respect of his resignations which needs to be brought to the attention of the shareholders of the Company (the “**Shareholder(s)**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Mr. HU for his valuable efforts and contributions to the Group during his tenure of office as a Director and a member of the Audit Committee.

## **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Ms. GE Lu (“**Ms. GE**”) has been appointed as a non-executive Director with effect from September 14, 2023.

Ms. GE, aged 52, was appointed as an external director of CR Health in August 2021. She is also a designated external director of the business unit(s) of China Resources Group. Ms. GE served as positions including the vice general manager, chief information officer of China Resources Pharmaceutical Commercial Group Limited (華潤醫藥商業集團有限公司) and China Resources Pharmaceutical Group Limited (華潤醫藥集團有限公司) and the general manager assistant of Beijing Pharmaceutical Co., Ltd. (北京醫藥股份有限公司) (now known as China Resources Pharmaceutical Commercial Group Limited (華潤醫藥商業集團有限公司)) from January 2010 to August 2021. Ms. GE has over 30 years of working experience in the pharmaceutical industry and specializes in supply chain management, logistics management and information systems management and planning in the pharmaceutical distribution field. Ms. GE holds a master’s degree of business administration from Tsinghua University (清華大學) and a bachelor’s degree of computer science from Beijing Jiaotong University (北京交通大學), and holds the title of Senior Engineer.

Ms. GE has entered into a service agreement with the Company for a term of three years from September 14, 2023 to September 13, 2026, which can be terminated by either party by giving to the other party not less than one month’s notice in writing. Ms. GE will not be entitled to any remuneration from the Group in respect of her appointment as a non-executive Director, and she has to abstain from voting on the relevant Board resolution in relation to the determination of her director’s remuneration amount.

Pursuant to the articles of association of the Company (the “**Articles**”), Ms. GE will hold office as a non-executive Director until the next annual general meeting of the Company and will be subject to retirement by rotation and re-election at that meeting.

As at the date of this announcement, Ms. GE holds 66,000 shares of the Company, and she also holds 2,000 shares of China Resources Beer (Holdings) Company Limited, which is an associated corporation of the Company. Save as disclosed in this announcement, Ms. GE does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed in this announcement, Ms. GE (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling

shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointments of Ms. GE that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Ms. GE for her new appointment.

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Mr. ZHOU Peng (“**Mr. ZHOU**”) has been appointed as an independent non-executive Director with effect from September 14, 2023.

Mr. ZHOU, aged 46, is the founder of Deep Blue Ridge Capital (“**DBR Capital**”). DBR Capital is a multi-strategy investment firm based in Hong Kong. Mr. ZHOU has 20 years of experience in global mergers and acquisitions and capital markets. Before founding DBR Capital, Mr. Zhou worked in Deutsche Bank (Hong Kong) and Credit Suisse (New York), and cooperated with the world’s top institutional and corporate clients to complete a number of cross-industry and cross-product transactions; and Mr. ZHOU’s career began in Bank of China. Mr. ZHOU holds a master’s degree in business administration from Columbia University in New York.

Mr. ZHOU has entered into a letter of appointment with the Company for a term of three years from September 14, 2023 to September 13, 2026, which can be terminated by either party by giving to the other party not less than one month’s notice in writing. The Board has resolved that Mr. ZHOU will be entitled to a director’s fee of HKD300,000 per annum, which was determined by the Board upon recommendation by the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to the prevailing market situation and his duties and responsibilities to the Group.

Pursuant to the Articles, Mr. ZHOU will hold office as an independent non-executive Director until the next annual general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

As at the date of this announcement, Mr. ZHOU does not have any interests in the shares or underlying shares of the Company and/or the associated corporations of the Company within the meaning of Part XV of the SFO. Save as disclosed in this announcement, Mr. ZHOU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointments of Mr. ZHOU that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Mr. ZHOU for his new appointment.

### **CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board announces that Mr. KWONG Kwok Kong has resigned as a member of the Remuneration Committee; Ms. GE has been appointed as a member of the Remuneration Committee; and Mr. ZHOU has been appointed as a member of the Audit Committee with effect from September 14, 2023.

By order of the Board  
**China Resources Medical Holdings Company Limited**  
**SONG Qing**  
*Chairman*

Shenzhen, September 14, 2023

*As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. SONG Qing, Mr. YU Hai, Mr. SHAN Baojie and Ms. YANG Min as executive Directors; Ms. GE Lu as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Mr. FU Tingmei and Mr. ZHOU Peng as independent non-executive Directors.*